Age-Related Macular Degeneration Therapeutic Pipeline Projects Vast Growth Ahead

  • Published: May 2017

According to a new research report “Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.

Browse Detailed Report Description at:

Age-related macular Degeneration therapeutics pipeline in 2017

The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.

Insights on pipeline segments

As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.

New innovating technologies offer development of promising drugs

Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.

Novel therapy for the development of Age-related macular degeneration therapeutics Pipeline

There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.

Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.

Age-related macular degeneration Therapeutic Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type